3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
December 2025 in “Biomedicines” This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
August 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” This study developed the CATNIP computational model, which uses biological and chemical information to successfully identify drug repurposing opportunities for various conditions, including Parkinson’s disease and Type 2 Diabetes.